/Companies

Pro Matix

Founded 2020 · 17 employees on LinkedIn · 1 known investors

Find your way into Pro Matix

Sign up to see every warm intro you have to Pro Matix

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Pro Matix team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Promatix develops bispecific antibody drug conjugates (ADCs) for solid tumours, using a proteomics-based platform to identify cancer surface marker pairs for cis-bispecific targeting. It is building a pipeline of cancer therapies with a lead program in colorectal cancer.

Founders & leadership

Board

GMGraeme Martin
Graeme MartinExecutive ChairmanVenture Partner at ALSA Ventures

Investors · 1

Companies House · registry record

View on Companies House ↗
Insolvency history
Registered name
PROMATIX LTD
Company number
09880263
Status
Dissolved
Company type
Private limited company
Incorporated
19 Nov 2015
Dissolved
4 Oct 2024
Registered office
9ensign House Admirals Way, Marsh Wall, London, E14 9XQ
Nature of business (SIC)
96090 — Other service activities n.e.c.
Accounts
last made up to 30 Nov 2022
Confirmation statement
last made up to 17 Nov 2022

Current officers

  • Christopher Haines Dickson — director, appointed 19 Nov 2015
  • Anoop Udayshinh Odedra — director, appointed 19 Nov 2015

Source: Companies House public register · retrieved 9 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.

Frequently asked questions

What does Pro Matix do?
Promatix develops bispecific antibody drug conjugates (ADCs) for solid tumours, using a proteomics-based platform to identify cancer surface marker pairs for cis-bispecific targeting. It is building a pipeline of cancer therapies with a lead program in colorectal cancer.
Who are Pro Matix's investors?
Pro Matix's investors include ALSA Ventures.